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A New, Standardized Approach
to Fracture Risk Interpretation
Richard D. Wasnich MD
Screening for osteoporosis has been hampered by the absence of
a standard approach to the interpretation of bone density and other
risk factors. A consensus conference of international experts has
now recommended a report which is based upon two concepts: (1)
comparison of an individual’s bone density to the mean value for 30
year old women, and (2) estimation of Remaining Lifetime Fracture
Probability (RLFP), based upon current age and bone density, life
expectancy, future bone loss, and other risk factors. This model is
dynamic and can be perfected as new risk factors become estab
lished. It a/so allows for estimation of therapeutic impact, and thus
improves and individualizes clinical decision making.
Despite the substantial body of evidence linking bone density to
future fracture risk, few successful osteoporosis screening pro
grams have been implemented. This can be attributed to two
obstacles:
1. The dearth of treatment options
2. The absence of a standardized interpretation of bone density
and fracture risk
With the availability of the bisphosphonate class of drugs, and the
future potential of estrogen analogues, the first obstacle has been
overcome. However, the second obstacle remains. A woman having
spinal bone density measured in Honolulu might receive an entirely
different report and interpretation if her hip bone density were
measured in New York. There has been no consensus regarding
which levels of bone density should be considered “treatment
thresholds.”
To address this important issue, a Consensus Conference of
international experts convened in Chantilly, Virginia in April,
1994.1 In order to understand the conclusions of the consensus
panel, some background is helpful.
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Bone mass (or density) is clinically useful for one reason; it is a
strong risk factor for osteoporotic fractures. It could also be argued
that bone density measurements are clinically useless unless they
influence the management of individual patients. The greatest,
potential application ofbone density is in patients without fractures,
but who are at risk for fractures. Since such patients have no
symptoms, and since there are usually no signs or other risk factors
that can successfully identify individual patients who are at risk,
there is a great clinical need for a practical way in which to identify
such patients. Otherwise pharmacologic agents, including estrogen
and especially anti-resorptive drugs, cannot be selectively pre
scribed for those with the greatest need.
If bone density measurements are to successfully fulfill this need,
then they must indicate to the physician how to manage the indi
vidual patient. If the patient is a 50-year-old woman, for example,
the question to be answered is: Should this patient receive
pharmacologic agents, or is only life-style advice required?
Bone density is the only known risk factor which has the potential
to answer this question. However a report stating that a patient has
a normal spine BMD of 1.0 gm/cm2does not answer the referring
physician’s question. Thus there is a need to develop a consensus on
how to provide a useful, clinical interpretation of bone mass
measurements.
EtiologicRisk Factors Versus Clinical Risk
Indicators
In order to understand the clinical use of bone density, it is helpful
to discuss risk factors in general. Risk factors have two possible
uses:
1. To search for disease etiology.
2. To clinically identify individuals at greatest risk of disease.
An example of an etiologic risk factor is smoking (for lung
cancer). In addition to explaining etiology, there are obvious public
health implications. On the other hand, smoking does not diagnose
lung cancer, even though it may raise the clinical suspicion.
There are some risk factors that are sufficiently strong that they
might be termed clinical risk indicators.’ The relationship of blood
pressure to cardiovascular and stroke risk is sufficiently strong that
the blood pressure measurement itself becomes an indication for
treatment. However, hypertension is not the only risk factor for
stroke. Likewise, bone mass is not the only risk factor for fracture.
The problem is this: How can these fracture risk data be applied
to clinical practice? It is certainly not intuitively apparent to the
clinician what a lumbar spine bone density of 1.0 gm/cm2means for
a 50-year-old patient. A variety of different interpretations have
been employed in the past. Before discussing each of these, the
consensus panel first discussed the requirements that an interpreta
tion should fulfill:
1. It should convey the fact that peak bone mass is as relevant as
is bone loss in determining lifetime fracture risk.
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Table 1.—The influence of age, initial BMD, and treatment upon future fracture
possiblility (NFP=number of fractures prevented; CFP=cost per fracture prevented).
Initial Initial RLFP 90% Reduction in Loss Rate
BMD Age (untreated) NFP CFP
510 50 0.46 0.38 17700
80 0.07 0.03 62050
360 50 2.50 1.98 3400
80 0.49 0.19 9650
290 50 5.00 3.75 1800
80 1.11 0.39 4500
2. It should illustrate how the individual compares to healthy,
young individuals of the same sex. For this purpose, the mean bone
density of healthy, 30-year-old women is considered the standard of
reference.
3. It should be intuitively apparent to both physician and patient.
4. It should provide an indication of absolute fracture risk.
5. It should estimate cumulative fracture risk over the patient’s
(estimated) remaining lifetime.
6. It should give the physician an objective basis upon which to
make therapeutic decisions. It should address this question: “Will
this patient benefit from pharmacologic treatment?”
7. It should also provide an estimate of therapeutic impact upon
fracture probability.
8. It should be adaptable to include risk factors other than bone
mass.
9. It should be sufficiently generic that various measurement
techniques and sites can be employed.
10. Since there are data indicating that density measurements at
various skeletal sites may contain independent predictive value for
fractures, our interpretation should be able to incorporate all avail
able information. Thus if two bone density measurements are
available, both should be used, rather than arbitrarily discarding one
value in favor of another.
Based upon these criteria, the consensus panel agreed upon the
following approach to fracture risk interpretation (Fig 1).
Based upon prior recommendations of the World Health Organi
zation, bone density values between - 1.0 and -2.5 SD are considered
osteopenic, and bone density values more than -2.55D are
osteoporotic. If the patient also has a history of nonviolent fracture,
she is classified as having severe osteoporosis. Although these
classifications provide a useful cross-sectional description, they are
insufficient for clinical decision making because they ignore age
(and therefore future years of bone loss and risk exposure).
Therefore the consensus panel adopted the concept of Remaining
Lifetime Fracture Probability (RLFP). Although the mathematical
modeling involved is complex, the concept is simple, as illustrated
in Fig 2. For purposes of discussion, assume that we are evaluating
a 50-year-old female, (Pt. “A” in Fig. 2). Her current bone density
is 0.95 SD below the mean for 30-year-olds; thus she has a T-score
of -0.95. Based upon life tables, we estimate that her life expectancy
is an additional 32 years. We will assume that, on average, she will
lose bone density at the rate of 1.5% per year over 32 years; if serial
bone density measurements are available, this figure can be appro
priately adjusted for the individual.
Based upon data from published studies relating fracture rates to
levels of bone mass/density, a fracture incidence rate can be as
signed to each age and bone density value. For example, our 50-
year-old patient with an initial heel value of 360 mg/cm2has a 0.5%
probability of a fracture (at any skeletal site) during the next year.
Each subsequent year, this rate increases as bone density declines.
RLFP is nothing more than the sum of all these rates over an
estimated remaining lifetime of 32 years. Thus this patient has an
estimated RLFP of 2.7, meaning that, on average, women like her
will experience 2.7 fractures in their remaining lifetime. This
number is, of course, associated with an error; some such individu
als will have more, and some will have fewer, fractures. Figure 2
also illustrates why bone density alone is not sufficient to make
clinical decisions. Patient B, who is 75 years old, has a T-score very
similar to Patient A, at-1.1. According to WHO guidelines, she is
osteopenic, whereas Patient A is normal. However Patient B has an
RLFP of only 0.5 (because of her shorter life expectancy), and a
treatment that stops bone loss would only lower her RLFP to 0.3.
Patient A, on the other hand, has an RLFP of 2.7, which could be
substantially lowered to 0.3 with treatment. Thus the “normal”
patient will receive much more benefit from pharmacologic treat
ment than will the older, “osteopenic” patient.
Although many fracture risk factors appear to be mediated via
bone mass, not all fracture risk factors are expressed, or mediated,
via bone mass. Falls, previous fractures, and perhaps age are
independently associated with fracture risk. Nevertheless, bone
mass is the most clinically useful of these indicators, for several
reasons. Although falls in the elderly have shown an association
with fracture, independent of bone mass, most fractures still occur
in patients with low bone mass. Also, the decision to preserve bone
mass should occur at much earlier ages, when the tendency to fall is
not yet apparent. Finally, preservation of bone mass is likely to
prevent many fractures even if falls cannot be completely elimi
nated. Age has also been associated with fracture risk, but of course
age itself is not modifiable. In any case, age is probably serving as
a surrogate for some other age-related factor.
Bone density is clinically useful because it represents a composite
and cumulative index of many other risk factors, both past and
present, including both genetic and life-style influences. Bone mass
frequently is a measurable expression of unknown. or unmeasurable,
risk factors. For example, adolescent nutrition and physical activity
may exert a strong influence upon attainment ofpeak bone mass, but
it maybe difficult, or impossible, to retrospectively estimate in a 50-
year-old patient.
It is not the purpose of this paper to review the data relating bone
mass to fracture risk. A number of studies have now shown that
Fig 1.—Each age and BMD level is associated with a fracture incidence rate; the
cumulative total of these rates represents cumulative fracture incidence (Remaining
Lifetime Fracture Probability).
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fracture risk increases progressively, and approximately exponen
tially, with decreasing levels of bone mass or density.3-5Thus
women with bone mass equal to the mean, one standard deviation
(SD) below the mean, and two SDs below the mean, have two, four,
and eight times greater risk, as compared to women with bone mass
one SD above the mean.
RLFP thus addresses the need for a cumulative estimate of
absolute fracture risk. It can also be applied to any bone density
measurement for which fracture incidence data are available. How
ever, the real advantage of the RLFP concept is the ability to
estimate the impact of therapeutic intervention. Although knowing
that this patient might experience fractures is more useful than
knowing that her BMD is normal, it still does not tell the clinician
what he or she most needs to know. Namely, can this risk be
significantly lowered ifpharmacologic treatment is prescribed? For
example, if an anti-resorptive drug is prescribed, what is the impact
upon fracture probability?
For the 50-year-old, an hypothetical, anti-resorptive drug that
stops bone loss would reduce her RLFP from 2.7 to 0.3 (potentially
preventing two fractures). However the 75-year-old, even if she
achieves the same prevention of bone loss, only reduces her RLFP
from 0.5 to 0.3 (preventing only 0.2 fractures). Because she has
fewer years of future bone loss and risk exposure, there is less
opportunity to reduce bone loss and fracture risk. Therefore, the
older women may receive greater benefit from non-pharmacologic
measures, such as calcium and Vitamin D supplementation, physi
cal activity regimens, and possibly measures to reduce the risk of
falls. The new treatments now becoming available are considerably
more efficacious. The average patient might gain 8-10% bone
density in the first three years of treatment, which translates into a
50% reduction in fracture risk. Thus treatment of older patients, like
the 75 year-old mentioned above, becomes cost-effective, particu
larly if the treatment has a good safety profile.
A final, potential use of the RLFP model is to estimate cost-
effectiveness of various treatment programs, shown in Table 1. If
the cost of estrogen replacement is $225 per year, and treatment
continues indefinitely, the cost perfracture-prevented can be esti
mated. Surprisingly, these estimates suggest that pharmacologic
treatments to reduce bone loss may be cost-effective even for
women in their 70’s, particularly for those at high fracture risk. Also
new treatments that are either more potent, or which have a longer
duration of action, could substantially improve the cost-effective
ness of treating the older woman. Although the reported bone mass
increases from anti-resorptive agents typically plateau after 2-3
years of treatment, women who maintain such an increase might
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have a much greater therapeutic benefit. For example, if the 50-
year-old woman described above, with an initial bone density of 360
mg/cm2and an RLFP of 2.7, experiences a 8% gain in bone density
which is subsequently maintained, it could translate into a
new RLFP of 0.2.
In conclusion, a standardized approach to bone density and
fracture risk interpretation is now available. Its use is expected to
facilitate improved clinical decision-making, and to allow for
individualized decisions for each patient.
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Fig 2.—Standardized approach to bone density and fracture risk interpretation
recommended by the Consensus Panel (1). Two patients with similar bone density, but
different fracture probabilities. The y-axis compares the measured value to the
average for 30 year old women. The arrow extends to mean life expectancy, and shows
expected future bone loss. The younger patient has more future bone loss and risk
exposure than the older patient, and may therefore receive greater therapeutic benefit.
Treatment I assumes complete prevention of bone loss. Treatment 2 assumes a 10%
increase in bone density.
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